Anti-Mouse CD80 Antibody (TKMG48) 

Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8⁺ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1^[1][2].

Rat IgG2a kappa

Rat IgG2a kappa, Isotype Control

Mouse

The anti-mouse CD80 antibody TKMG48 increases free mPD-L1 levels on LPS-treated primary mouse splenic cDCs, with greater activity than Abatacept (HY-108829) in this context^[1].
Anti-Mouse CD80 Antibody (TKMG48) dose-dependently facilitates PD-1-EC binding to PD-L1 on T cell lymphoma (IIAdL) cells expressing PD-L1 and CD80 in cis, without disrupting CD80-CTLA4 binding and only weakly reducing CD80-CD28 binding^[2].
Anti-Mouse CD80 Antibody (TKMG48) dose-dependently reduces IL-2 production by PD-1-expressing DO11.10 T cell hybridoma cells stimulated with ovalbumin peptide-pulsed B lymphoma (IIAdL) cells, with no effect on PD-1 signaling-deficient mutant cells^[2].
Anti-Mouse CD80 Antibody (TKMG48) weakly reduces IL-2 production by T cells stimulated with CD80-only B lymphoma (IIAdL) cells, but has no effect when APCs express both CD80 and CD86^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse CD80 Antibody (TKMG48) robustly reduces spondyloarthritis severity, T cell activation, and pro-inflammatory cytokine production in both early and chronic disease stages^[2].
Anti-Mouse CD80 Antibody (TKMG48) reduces histological signs of sialadenitis and dacryadenitis in a mouse model of Sjögren’s syndrome^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

12519  [NCBI]

Q00609

CD80

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[Anti-Mouse CD80 Antibody (TKMG48)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Oxley E P, et al. Context-restricted PD-(L) 1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity[J]. Cell Reports, 2024, 43(10).

  [2]. Grebinoski S, et al. Catch and release: freeing up PD-L1 ameliorates autoimmunity. Nat Immunol. 2022;23(3):344-346.